395 related articles for article (PubMed ID: 36828429)
21. Dysbiosis of Gut Microbiota Contributes to Uremic Cardiomyopathy via Induction of IFNγ-Producing CD4
Han B; Zhang X; Wang L; Yuan W
Microbiol Spectr; 2023 Feb; 11(1):e0310122. PubMed ID: 36788674
[TBL] [Abstract][Full Text] [Related]
22. Protein-bound uremic toxins (PBUTs) in chronic kidney disease (CKD) patients: Production pathway, challenges and recent advances in renal PBUTs clearance.
Daneshamouz S; Eduok U; Abdelrasoul A; Shoker A
NanoImpact; 2021 Jan; 21():100299. PubMed ID: 35559786
[TBL] [Abstract][Full Text] [Related]
23. Blueberry, cranberry, raspberry, and strawberry as modulators of the gut microbiota: target for treatment of gut dysbiosis in chronic kidney disease? From current evidence to future possibilities.
Coutinho-Wolino KS; Melo MFS; Mota JC; Mafra D; Guimarães JT; Stockler-Pinto MB
Nutr Rev; 2024 Jan; 82(2):248-261. PubMed ID: 37164634
[TBL] [Abstract][Full Text] [Related]
24. Design and rationale for an open-label, randomized, controlled pilot trial to evaluate the changes in blood uremic toxins in patients with chronic kidney disease by dietary therapy with sake lees.
Tokumaru T; Toyama T; Nakade Y; Ogura H; Oshima M; Nakagawa S; Furuichi M; Kitajima S; Sakai N; Shimizu M; Iwata Y; Wada T
Clin Exp Nephrol; 2024 May; 28(5):440-446. PubMed ID: 38340247
[TBL] [Abstract][Full Text] [Related]
25. Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease.
Prokopienko AJ; Nolin TD
Expert Rev Clin Pharmacol; 2018 Jan; 11(1):71-82. PubMed ID: 28905671
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach.
Mishima E; Fukuda S; Mukawa C; Yuri A; Kanemitsu Y; Matsumoto Y; Akiyama Y; Fukuda NN; Tsukamoto H; Asaji K; Shima H; Kikuchi K; Suzuki C; Suzuki T; Tomioka Y; Soga T; Ito S; Abe T
Kidney Int; 2017 Sep; 92(3):634-645. PubMed ID: 28396122
[TBL] [Abstract][Full Text] [Related]
27. Uremic Toxins and Protein-Bound Therapeutics in AKI and CKD: Up-to-Date Evidence.
Chen JH; Chiang CK
Toxins (Basel); 2021 Dec; 14(1):. PubMed ID: 35050985
[TBL] [Abstract][Full Text] [Related]
28. Role of the Microbiome in Gut-Heart-Kidney Cross Talk.
Glorieux G; Nigam SK; Vanholder R; Verbeke F
Circ Res; 2023 Apr; 132(8):1064-1083. PubMed ID: 37053274
[TBL] [Abstract][Full Text] [Related]
29. Microbiome in Chronic Kidney Disease (CKD): An Omics Perspective.
Lohia S; Vlahou A; Zoidakis J
Toxins (Basel); 2022 Feb; 14(3):. PubMed ID: 35324673
[TBL] [Abstract][Full Text] [Related]
30. Gut Microbiota Mediates the Protective Effects of Traditional Chinese Medicine Formula Qiong-Yu-Gao against Cisplatin-Induced Acute Kidney Injury.
Zou YT; Zhou J; Zhu JH; Wu CY; Shen H; Zhang W; Zhou SS; Xu JD; Mao Q; Zhang YQ; Long F; Li SL
Microbiol Spectr; 2022 Jun; 10(3):e0075922. PubMed ID: 35481834
[TBL] [Abstract][Full Text] [Related]
31. Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease.
Gryp T; De Paepe K; Vanholder R; Kerckhof FM; Van Biesen W; Van de Wiele T; Verbeke F; Speeckaert M; Joossens M; Couttenye MM; Vaneechoutte M; Glorieux G
Kidney Int; 2020 Jun; 97(6):1230-1242. PubMed ID: 32317112
[TBL] [Abstract][Full Text] [Related]
32. Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins.
Lau WL; Savoj J; Nakata MB; Vaziri ND
Clin Sci (Lond); 2018 Mar; 132(5):509-522. PubMed ID: 29523750
[TBL] [Abstract][Full Text] [Related]
33. Uremic Toxin-Producing
Shivani S; Kao CY; Chattopadhyay A; Chen JW; Lai LC; Lin WH; Lu TP; Huang IH; Tsai MH; Teng CH; Wu JJ; Hsieh YH; Wang MC; Chuang EY
Front Cell Infect Microbiol; 2022; 12():726256. PubMed ID: 35558102
[TBL] [Abstract][Full Text] [Related]
34. Effects of Uremic Toxins from the Gut Microbiota on Bone: A Brief Look at Chronic Kidney Disease.
Black AP; Cardozo LF; Mafra D
Ther Apher Dial; 2015 Oct; 19(5):436-40. PubMed ID: 25944654
[TBL] [Abstract][Full Text] [Related]
35. Dietary strategies for gut-derived protein-bound uremic toxins and cardio-metabolic risk factors in chronic kidney disease: A focus on dietary fibers.
Melekoglu E; Samur FG
Crit Rev Food Sci Nutr; 2023; 63(19):3994-4008. PubMed ID: 34704501
[TBL] [Abstract][Full Text] [Related]
36. Impact of Altered Intestinal Microbiota on Chronic Kidney Disease Progression.
Castillo-Rodriguez E; Fernandez-Prado R; Esteras R; Perez-Gomez MV; Gracia-Iguacel C; Fernandez-Fernandez B; Kanbay M; Tejedor A; Lazaro A; Ruiz-Ortega M; Gonzalez-Parra E; Sanz AB; Ortiz A; Sanchez-Niño MD
Toxins (Basel); 2018 Jul; 10(7):. PubMed ID: 30029499
[TBL] [Abstract][Full Text] [Related]
37. Can Resveratrol Supplementation Reduce Uremic Toxin Plasma Levels From the Gut Microbiota in Nondialyzed Patients With Chronic Kidney Disease?
Alvarenga L; Cardozo LFMF; Leal VO; Kemp JA; Saldanha JF; Ribeiro-Alves M; Meireles T; Nakao LS; Mafra D
J Ren Nutr; 2022 Nov; 32(6):685-691. PubMed ID: 35122992
[TBL] [Abstract][Full Text] [Related]
38. Gut microbiome in chronic kidney disease: challenges and opportunities.
Nallu A; Sharma S; Ramezani A; Muralidharan J; Raj D
Transl Res; 2017 Jan; 179():24-37. PubMed ID: 27187743
[TBL] [Abstract][Full Text] [Related]
39. Emodin via colonic irrigation modulates gut microbiota and reduces uremic toxins in rats with chronic kidney disease.
Zeng YQ; Dai Z; Lu F; Lu Z; Liu X; Chen C; Qu P; Li D; Hua Z; Qu Y; Zou C
Oncotarget; 2016 Apr; 7(14):17468-78. PubMed ID: 27003359
[TBL] [Abstract][Full Text] [Related]
40. Gut Dysbiosis and Kidney Diseases.
Cao C; Zhu H; Yao Y; Zeng R
Front Med (Lausanne); 2022; 9():829349. PubMed ID: 35308555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
